{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T07:12:00Z","timestamp":1688109120792},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Vascular Surgery"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1053\/j.semvascsurg.2011.10.005","type":"journal-article","created":{"date-parts":[[2011,12,11]],"date-time":"2011-12-11T12:59:37Z","timestamp":1323608377000},"page":"172-179","source":"Crossref","is-referenced-by-count":4,"title":["Influence and Critique of the JUPITER Trial (Statins v No Statins for Primary Prevention of Cardiovascular Events in Patients with Normal Lipids and Elevated C-Reactive Protein)"],"prefix":"10.1053","volume":"24","author":[{"given":"Russell H.","family":"Samson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak G.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semvascsurg.2011.10.005_bib1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4330\/wjc.v3.i7.207","article-title":"JUPITER and satellites: clinical implications of the JUPITER study and its secondary analyses","volume":"3","author":"Kostapanos","year":"2011","journal-title":"World J Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3810\/pgm.2009.05.2010","article-title":"The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin)","volume":"121","author":"O'Keefe","year":"2009","journal-title":"Postgrad Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archinternmed.2010.189","article-title":"By Jove! What is a clinician to make of JUPITER?","volume":"170","author":"Kaul","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/DDDT.S10812","article-title":"Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease\u2014a perspective","volume":"4","author":"Kones","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/CIRCOUTCOMES.108.832592","article-title":"From here to JUPITER","volume":"2","author":"Spatz","year":"2009","journal-title":"Circ Qual Outcomes"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib7","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1056\/NEJMe086509","article-title":"JUPITER clinical directions\u2014polling results","volume":"360","author":"Kritek","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archinternmed.2010.184","article-title":"Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy","volume":"170","author":"de Lorgeril","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/archinternmed.2010.168","article-title":"Cholesterol-lowering therapy for primary prevention","volume":"170","author":"Green","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ahj.2011.03.032","article-title":"Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"162","author":"Albert","year":"2011","journal-title":"Am Heart J"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib11","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50mg\/dl with rosuvastatin","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib12","article-title":"Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: a post hoc analysis of the JUPITER Trial","author":"Brookhart","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurheartj\/ehq370","article-title":"Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk \u22655% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities","volume":"32","author":"Koenig","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIRCOUTCOMES.110.938118","article-title":"Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk","volume":"3","author":"Ridker","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","article-title":"Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)","volume":"106","author":"Ridker","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-152-8-201004200-00005","article-title":"Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial","volume":"152","author":"Glynn","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib17","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCOUTCOMES.109.848473","volume":"6","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/CIRCULATIONAHA.109.874834","article-title":"Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)","volume":"121","author":"Everett","year":"2010","journal-title":"Circulation"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib21","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.amjcard.2010.08.025","article-title":"The JUPITER trial: responding to the critics","volume":"106","author":"Ridker","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/1740774511407939","article-title":"A tale of three labels: translating the JUPITER trial data into regulatory claims","volume":"8","author":"Ridker","year":"2011","journal-title":"Clin Trials"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib25","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.amjcard.2010.06.008","article-title":"The editor's roundtable: JUPITER follow-up","volume":"107","author":"Friedewald","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib26","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/archinte.161.11.1405","article-title":"Use of statins and the subsequent development of deep vein thrombosis","volume":"161","author":"Ray","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib27","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib28","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.jacc.2009.10.006","article-title":"Clinical implications of JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a US population: insights from the ARIC (Atherosclerosis Risk in Communities) study","volume":"54","author":"Yang","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/sim.4780071204","article-title":"Stopping rules and estimation problems in clinical trials","volume":"7","author":"Hughes","year":"1988","journal-title":"Stat Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/sim.4780090612","article-title":"Estimation issues in clinical trials and overviews","volume":"9","author":"Pocock","year":"1990","journal-title":"Stat Med"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib31","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized trials stopped early for benefit: a systematic review","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCOUTCOMES.109.850404","article-title":"JUPITER","volume":"2","author":"Vaccarino","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib34","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1185\/03007995.2010.516994","article-title":"Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER","volume":"26","author":"Slejko","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2008.12.010","article-title":"Prevalence of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study","volume":"53","author":"Michos","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib36","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.amjcard.2009.07.033","article-title":"Another look at the results of the JUPITER trial","volume":"104","author":"Kappagoda","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.semvascsurg.2011.10.005_bib37","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCGENETICS.110.957431","article-title":"Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction","volume":"3","author":"Shah","year":"2010","journal-title":"Circ Cardiovasc Genet"}],"container-title":["Seminars in Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796711000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895796711000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T23:54:02Z","timestamp":1543362842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895796711000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0895796711000652"],"URL":"https:\/\/doi.org\/10.1053\/j.semvascsurg.2011.10.005","relation":{},"ISSN":["0895-7967"],"issn-type":[{"value":"0895-7967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}